The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Johnson & Johnson

NYSE: JNJ
Last

(U.S.) $99.84

Today's change0.00 0.00%
Updated July 30 4:00 PM EDT. Delayed by at least 15 minutes.
 

Johnson & Johnson

NYSE: JNJ
Last

(U.S.) $99.84

Today's change0.00 0.00%
Updated July 30 4:00 PM EDT. Delayed by at least 15 minutes.

Johnson & Johnson closed at (U.S.)$99.84.

Over the last five days, shares have lost 0.36% and sit 4.98% above their 52-week low. This security has underperformed the S&P 500 by 9.44% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $99.84
  • High--
  • Low--
  • Bid / Ask(U.S.) $99.15 / (U.S.) $100.47
  • YTD % change-4.52%
  • Volume0
  • Average volume (10-day)6,708,654
  • Average volume (1-month)7,026,673
  • Average volume (3-month)7,292,437
  • 52-week range(U.S.) $95.10 to (U.S.) $109.49
  • Beta0.61
  • Trailing P/E17.58×
  • P/E 1 year forward16.16×
  • Forward PEG3.47×
  • Indicated annual dividend(U.S.) $3.00
  • Dividend yield3.00%
  • Trailing EPS(U.S.) $5.68
Updated July 30 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+22.41%

Based on its net profit margin of 22.41%, Johnson & Johnson is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 29, 201506/29/2015Mar 29, 201503/29/2015Dec 28, 201412/28/2014Sep 28, 201409/28/2014
Revenue17,78717,37418,25418,467
Total other revenue--------
Total revenue17,78717,37418,25418,467
Gross profit12,43012,09212,40113,068
Total cost of revenue5,3575,2825,8535,399
Total operating expense12,04611,79915,55111,657
Selling / general / administrative5,3844,8475,8225,468
Research & development2,1291,8992,6352,023
Depreciation / amortization--------
Interest expense (income), net operating--138139130
Unusual expense (income)001560
Other operating expenses, total-931-4321,016-1,347
Operating income5,7415,5752,7036,810
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax5,7415,5752,7036,810
Income after tax4,5164,3202,5214,749
Income tax, total1,2251,2551822,061
Net income4,5164,3202,5214,749
Total adjustments to net income--------
Net income before extra. items4,5164,3202,5214,749
Minority interest----0--
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items4,5164,3202,5214,749
Inc. avail. to common incl. extra. items4,5164,3202,5214,749
Diluted net income4,5164,3202,5214,749
Dilution adjustment0--0--
Diluted weighted average shares2,8162,8262,8422,864
Diluted EPS excluding extraordinary itemsvalue per share1.601.530.891.66
Dividends per sharevalue per share0.750.700.700.70
Diluted normalized EPSvalue per share1.671.380.372.00